Search Result

Results for "

type 2 diabetes mellitus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) Acyltransferase (2) Adenosine Receptor (1) Akt (2) Aldehyde Dehydrogenase (ALDH) (1) Aldose Reductase (2) AMPK (3) Amylases (3) Amylin Receptor (1) Amyloid-β (2) Apoptosis (4) Arrestin (1) Autophagy (1) Biochemical Assay Reagents (1) Calcium Channel (1) Caspase (2) CGRP Receptor (1) Cholinesterase (ChE) (1) Cytochrome P450 (2) Dipeptidyl Peptidase (34) E1/E2/E3 Enzyme (1) Endogenous Metabolite (4) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (2) Fatty Acid Synthase (FASN) (1) FBPase (1) FGFR (1) Free Fatty Acid Receptor (6) Fungal (2) FXR (1) G protein-coupled Bile Acid Receptor 1 (2) GCGR (10) GLP Receptor (13) Glucocorticoid Receptor (1) GLUT (2) Glycosidase (12) GPR109A (2) GPR119 (4) GSK-3 (2) HDAC (1) Histone Demethylase (1) IFNAR (1) IKK (3) Insulin Receptor (4) Interleukin Related (5) Isotope-Labeled Compounds (14) JNK (2) Keap1-Nrf2 (2) LOX-1 (1) LRRK2 (3) MDM-2/p53 (1) Mineralocorticoid Receptor (5) mTOR (1) Neuropeptide Y Receptor (1) NF-κB (6) NOD-like Receptor (NLR) (2) P-glycoprotein (6) p38 MAPK (2) PARP (2) PEPCK (1) Phosphatase (8) PI3K (1) PKA (1) PKD (3) Potassium Channel (10) PPAR (8) PROTACs (1) Reactive Oxygen Species (ROS) (3) Reference Standards (18) Ribosomal S6 Kinase (RSK) (1) SGLT (10) Sodium Channel (1) Somatostatin Receptor (4) Tau Protein (1) TNF Receptor (3) Toll-like Receptor (TLR) (1) Topoisomerase (1) VDAC (1) Virus Protease (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (17) Endocrinology (8) Infection (3) Inflammation/Immunology (15) Metabolic Disease (139) Neurological Disease (10)
Oligonucleotides:	Antisense Oligonucleotides (4)

157

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: C-type Lectin-like Receptors (CTLRs) PCSK9 Scavenger Receptor Class B type I (SR-BI）

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0014

Liraglutide 35+ Cited Publications	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-111372

Finerenone 5+ Cited Publications BAY 94-8862	Mineralocorticoid Receptor	Cardiovascular Disease Metabolic Disease
Finerenone (BAY 94-8862) is a third-generation, selective, and orally active nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀ = 18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (> 500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-15209

Repaglinide 2 Publications Verification AG-EE 623ZW	Potassium Channel	Metabolic Disease Cancer
Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus .

HY-19904

Adomeglivant 4 Publications Verification LY2409021	GCGR	Metabolic Disease
Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus .

HY-10285

Saxagliptin 5+ Cited Publications BMS-477118	Dipeptidyl Peptidase	Metabolic Disease
Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research .

HY-153865

Lotiglipron PF-07081532	GLP Receptor	Metabolic Disease
Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) .

HY-15461

Ertugliflozin 5 Publications Verification PF-04971729	SGLT	Metabolic Disease
Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-P4070

Insulin icodec	Insulin Receptor	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA_1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .

HY-19947

PF-06291874 1 Publications Verification Glucagon receptor antagonists-4	GCGR	Metabolic Disease
PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .

HY-B0422

Nateglinide A4166; Senaglinide	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K ⁺ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .

HY-15461A

Ertugliflozin L-pyroglutamic acid 5 Publications Verification PF-04971729 L-pyroglutamic acid	SGLT	Metabolic Disease
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-14806

Teneligliptin 5+ Cited Publications MP-513	Dipeptidyl Peptidase	Cardiovascular Disease Neurological Disease Metabolic Disease
Teneligliptin (MP-513) hydrobromide hydrate is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC₅₀s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide hydrate improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus .

HY-B0254

Glipizide 2 Publications Verification CP 28720; K 4024	Potassium Channel	Metabolic Disease Cancer
Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(K_ATP) channels among β cells of pancreatic islets of Langerhans .

HY-112668A

Retagliptin 1 Publications Verification SP2086	Dipeptidyl Peptidase	Metabolic Disease
Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research .

HY-15497

AZD7687 1 Publications Verification	Acyltransferase	Metabolic Disease
AZD7687 is a potent, selective, reversible and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor with an IC₅₀ of 80 nM for human DGAT1. AZD7687 can be used for type 2 diabetes mellitus and obesity research .

HY-15408

Trelagliptin 1 Publications Verification SYR-472	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-12066

GSK1292263 5 Publications Verification	GPR119	Metabolic Disease Inflammation/Immunology
GSK-1292263 is an orally available GPR119 agonist with pEC₅₀s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-147257

Cofrogliptin HSK7653	Dipeptidyl Peptidase	Metabolic Disease
Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .

HY-P99614

Fazpilodemab BFKB8488A; RG-7992; RO-7040551	FGFR	Metabolic Disease
Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .

HY-14806A

Teneligliptin hydrobromide 5+ Cited Publications MP-513 hydrobromide	Dipeptidyl Peptidase NOD-like Receptor (NLR) Interleukin Related AMPK Reactive Oxygen Species (ROS) Apoptosis p38 MAPK NF-κB JNK	Cardiovascular Disease Neurological Disease Metabolic Disease
Teneligliptin (MP-513) hydrobromide is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC₅₀s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus .

HY-112668

Retagliptin phosphate 1 Publications Verification SP2086 phosphate	Dipeptidyl Peptidase	Metabolic Disease
Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research .

HY-16448

Saxagliptin hydrochloride 5+ Cited Publications BMS-477118 hydrochloride	Dipeptidyl Peptidase	Metabolic Disease
Saxagliptin hydrochloride (BMS-477118 hydrochloride) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin hydrochloride has the peotential for type 2 diabetes mellitus research .

HY-15408A

Trelagliptin succinate 1 Publications Verification SYR-472 succinate	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-117103

AMG131 INT131	PPAR	Metabolic Disease
AMG131 (INT131) is a potent non-thiazolidinedione (TZD) selective peroxisome proliferator-activated receptor γ modulator (SPPARM). AMG131 binds to PPARγ within the same binding pocket as the TZDs, but occupies a unique space in the pocket and contacts the receptor at distinct points from the TZDs. AMG131 is promising for research of type-2 diabetes mellitus .

HY-10286

Dutogliptin PHX-1149 free base	Dipeptidyl Peptidase	Metabolic Disease
Dutogliptin (PHX-1149 free base) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.

HY-W145497

D-(+)-Sorbose	Insulin Receptor	Metabolic Disease
D-(+)-Sorbose, an active enantiomer of D-Sorbose, which inhibits disaccharidase activity and demonstrates suppressive action on postprandial blood levels of glucose and insulin in the rat. D-sorbose acts as a sweetener may contribute to the prevention of lifestyle-related diseases, such as type 2 diabetes mellitus .

HY-15209S

Repaglinide-d5 AG-EE 623ZW d₅	Isotope-Labeled Compounds Potassium Channel	Metabolic Disease
Repaglinide-d₅ is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-100428

Netoglitazone MCC-555; Isaglitazone	PPAR	Metabolic Disease
Netoglitazone (MCC-555) is an orally active PPARγ ligand with an EC₅₀ of 8 μM. Netoglitazone mediates cell type-specific functional regulation, and modulates the transcriptional activity of PPARγ as a full agonist, partial agonist or antagonist. Netoglitazone induces adipogenesis, inhibits osteoblastogenesis, alters the weight of extramedullary fat depots and enhances insulin sensitivity. Netoglitazone reduces blood glucose levels. Netoglitazone can be used in research related to type 2 diabetes and non-insulin-dependent diabetes mellitus .

HY-139276

Pal-Glu(OSu)-OH	GLP Receptor	Others
Pal-Glu(OSu)-OH is a side chain of Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used for type 2 diabetes mellitus research .

HY-114191B

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

HY-123377A

Fotagliptin benzoate SAL067	Dipeptidyl Peptidase	Metabolic Disease
Fotagliptin benzoate is a Dipeptidyl Peptidase IV (DPP-4) inhibitor (IC₅₀=2.27 nM). Fotagliptin benzoate displays great security in rat and dog. Fotagliptin benzoate can be used for Type 2 diabetes mellitus research .

HY-10285A

Saxagliptin hydrate 5+ Cited Publications BMS-477118 hydrate	Dipeptidyl Peptidase	Metabolic Disease
Saxagliptin hydrate (BMS-477118 hydrate) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin hydrate has the peotential for type 2 diabetes mellitus research .

HY-147645

FBPase-IN-2	FBPase	Metabolic Disease
FBPase-IN-2 (Compound HS36) is a covalent FBPase inhibitor with an IC₅₀ value of 0.15 μM for wild-type FBPase. FBPase-IN-2 inhibits glucose production in primary mouse hepatocytes via gluconeogenesis modulation. FBPase-IN-2 can be used for the research of type 2 diabetes mellitus .

HY-15209R

Repaglinide (Standard) AG-EE 623ZW (Standard)	Reference Standards Potassium Channel	Metabolic Disease Cancer
Repaglinide (Standard) is the analytical standard of Repaglinide. This product is intended for research and analytical applications. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus .

HY-W587977

3-Hydroxypalmitoylcarnitine 3-Hydroxyhexadecanoylcarnitine	Biochemical Assay Reagents	Cardiovascular Disease Metabolic Disease
3-Hydroxypalmitoylcarnitine (3-Hydroxyhexadecanoylcarnitine) is an acylcarnitine. Elevated levels of 3-Hydroxypalmitoylcarnitine are associated with cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM) .

HY-B0254S

Glipizide-d11	Isotope-Labeled Compounds Potassium Channel	Metabolic Disease
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .

HY-B0254R

Glipizide (Standard) CP 28720 (Standard); K 4024 (Standard)	Reference Standards Potassium Channel	Metabolic Disease
Glipizide (Standard) is the analytical standard of Glipizide. This product is intended for research and analytical applications. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (K_ATP) channels among β cells of pancreatic islets of Langerhans .

HY-101746

GSK376501A	PPAR	Metabolic Disease
GSK376501A is a selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator for the treatment of type 2 diabetes mellitus .

HY-123377

Fotagliptin SAL067 free base	Dipeptidyl Peptidase	Metabolic Disease
Fotagliptin is a Dipeptidyl Peptidase IV (DPP-4) inhibitor (IC₅₀=2.27 nM). Fotagliptin displays great security in rat and dog. Fotagliptin can be used for Type 2 diabetes mellitus research .

HY-10449A

Luseogliflozin hydrate TS 071 hydrate	SGLT	Metabolic Disease
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-19779

JTT 551	Phosphatase	Metabolic Disease
JTT 551 is selective a protein tyrosine phosphatase 1B (PTP1B) inhibitor, with K_is of 0.22 μM and 9.3 μM for PTP1B and TCPTP (T-cell protein tyrosine phosphatase), respectively; JTT 551 can be used in the research of type 2 diabetes mellitus.

HY-15461R

Ertugliflozin (Standard) PF-04971729 (Standard)	Reference Standards SGLT	Metabolic Disease
Ertugliflozin (Standard) is the analytical standard of Ertugliflozin. This product is intended for research and analytical applications. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-19771

GSK 3039294 GSK294; amyloid P-IN-1	Amyloid-β	Cancer
amyloid P-IN-1 is used in the research of diseases or disorders wherein depletion of serum amyloid P component (SAP), including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.

HY-153113

Rongliflozin DJT1116PG	SGLT	Endocrinology
Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-P0014AS

Liraglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor	Metabolic Disease
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-B0422S

Nateglinide-d5 A4166 d₅; Senaglinide d₅	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide-d₅ is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

HY-128781

Glucagon receptor antagonist-5	GCGR	Metabolic Disease
Glucagon receptor antagonist-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (K_i=32 nM). Glucagon receptor antagonist-5 has potential for the treatment of type 2 diabetes mellitus (T2DM) .

HY-P11321A

IUB0271 hydrochloride acyl-GIP hydrochloride	Insulin Receptor	Metabolic Disease
IUB0271 (acyl-GIP) hydrochloride is a fatty acylated and long-acting glucose-dependent insulinotropic polypeptide (GIP). IUB0271 hydrochloride increases cFos neuronal activity in hypothalamic feeding centers and decreases body weight, food intake and glycemia in DIO mouse models, and these effects depend on CNS-GIPR signaling. IUB0271 hydrochloride can be used for type 2 diabetes mellitus (T2DM) and obesity research .

HY-14928S1

Lobeglitazone-d4	Isotope-Labeled Compounds Others	Metabolic Disease
Lobeglitazone-d₄ is deuterium labeled Lobeglitazone. Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library

1,113 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 1,113 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area

HY-P0014

Liraglutide 35+ Cited Publications	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P4070

Insulin icodec	Insulin Receptor	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA_1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P0014AS

Liraglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor	Metabolic Disease
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P11321A

IUB0271 hydrochloride acyl-GIP hydrochloride	Insulin Receptor	Metabolic Disease
IUB0271 (acyl-GIP) hydrochloride is a fatty acylated and long-acting glucose-dependent insulinotropic polypeptide (GIP). IUB0271 hydrochloride increases cFos neuronal activity in hypothalamic feeding centers and decreases body weight, food intake and glycemia in DIO mouse models, and these effects depend on CNS-GIPR signaling. IUB0271 hydrochloride can be used for type 2 diabetes mellitus (T2DM) and obesity research .

HY-P11321

IUB0271 acyl-GIP	Insulin Receptor	Metabolic Disease
IUB0271 (acyl-GIP) is a fatty acylated and long-acting glucose-dependent insulinotropic polypeptide (GIP). IUB0271 increases cFos neuronal activity in hypothalamic feeding centers and decreases body weight, food intake and glycemia in DIO mouse models, and these effects depend on CNS-GIPR signaling. IUB0271 can be used for type 2 diabetes mellitus (T2DM) and obesity research .

HY-P11043

GEP44	GLP Receptor Neuropeptide Y Receptor Arrestin	Metabolic Disease
GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .

HY-P0014S2

Liraglutide-13C6,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P11736

mcIRBP-9	NF-κB	Metabolic Disease
mcIRBP-9 is an orally active NF-κB inhibitor. mcIRBP-9 reduces the levels of TNF-α, IL-1β and TGF-β1 in renal tissues, and decreases LPS-induced IL-1β production. mcIRBP-9 can be used in research related to diabetic nephropathy and type 2 diabetes mellitus .

HY-P11584

KBP-066A	Amylin Receptor CGRP Receptor	Metabolic Disease
KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99646

Golocdacimab 2 Publications Verification MEDI6570	LOX-1	Metabolic Disease Inflammation/Immunology
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus .

HY-P99614

Fazpilodemab BFKB8488A; RG-7992; RO-7040551	FGFR	Metabolic Disease
Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .

HY-P992007

PF-06293620 RN909	GCGR	Metabolic Disease
PF-06293620 (RN909) is a monoclonal antibody antagonist of the glucagon receptor. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1021

Vincamine 1 Publications Verification	Apocynaceae Cardiovascular Disease Alkaloids Classification of Application Fields Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	Free Fatty Acid Receptor
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-N1970

5,7-Dihydroxychromone 2 Publications Verification	Structural Classification Flavonoids other families Phenols Polyphenols Plants Isoflavones Source Classification	Keap1-Nrf2 Caspase PARP Fungal
5,7-Dihydroxychromone is a flavonoid compound with antioxidant properties. 5,7-Dihydroxychromone induces Nrf2 nuclear translocation, increases Nrf2/ARE binding activity, and up-regulates Nrf2-dependent antioxidant genes HO-1, NQO1, GCLc. 5,7-Dihydroxychromone attenuates excessive ROS generation, inhibits activated caspase-3, caspase-9, cleaved PARP expression, and prevents neuronal apoptosis and cell death. 5,7-Dihydroxychromone increases LXRα and PPARγ mRNA expression, induces preadipocyte differentiation, and regulates blood glucose levels. 5,7-Dihydroxychromone inhibits radial growth of soil pathogenic fungi, radicle elongation of select seedlings, and transiently inhibits Bradyrhizobium sp. growth in high mannitol medium. 5,7-Dihydroxychromone can be used for the research of Parkinson’s disease, type 2 diabetes mellitus and pathogenic fungal infection .

HY-N0500

Mogroside III	Triterpenes Classification of Application Fields Terpenoids Cucurbitaceae Metabolic Disease Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Disease Research Fields Sweeteners Source Classification Food Research	Glycosidase Autophagy
Mogroside III is a triterpenoid glycoside. Mogroside III exhibits maltase inhibitory effect with an IC₅₀ value of 1.6 mM. Mogroside III enhances oocyte developmental potential by promoting autophagy in cumulus cells. Mogroside III, as the active ingredient of the low-polarity glycoside component (L-SGgly), L-SGgly can increase serum GLP-1 levels, improve insulin resistance, and reduce IL-6 levels, and has hypoglycemic, lipid-regulating and anti-inflammatory effects. Mogroside III can be used for the studies of type 2 diabetes mellitus (T2DM) and assisted reproductive technology .

HY-155157

PF-07247685	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-N0857

Deoxyandrographolide 1 Publications Verification	Structural Classification Acanthaceae Simsia foetida (Cav.) S.F.Blake Terpenoids Diterpenoids Plants Source Classification	GLUT HDAC Virus Protease PI3K AMPK Akt Histone Demethylase MDM-2/p53 IFNAR Reactive Oxygen Species (ROS)
Deoxyandrographolide is an orally active lactone found in the Andrographis paniculata Nees. Deoxyandrographolide shows a K_D of 38.4 μM of HDAC1. Deoxyandrographolide enhances GLUT4 plasma membrane translocation, activates PI3K and AMPK-dependent signaling pathways, suppresses fasting blood glucose, serum insulin, triglycerides, and LDL-cholesterol levels. Deoxyandrographolide enhances HDAC1 expression via inhibited ubiquitination degradation, represses H3K4me3, improves chromosome stability, and restrains aging biomarkers p16, p21, γH2A.X, p53 and ROS production. Deoxyandrographolide interacts with Foot-and-Mouth Disease Virus 3Cpro active site, inhibits protease and IFN-antagonist activity, derepresses ISG expression, and inhibits viral replication. Deoxyandrographolide can be used for the researches of type 2 diabetes mellitus, vascular senescence and virus infection .

HY-155156

PF-07238025	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-N1970R

5,7-Dihydroxychromone (Standard)	Structural Classification Flavonoids other families Phenols Polyphenols Plants Isoflavones Source Classification	Reference Standards Keap1-Nrf2 Caspase PARP Fungal
5,7-Dihydroxychromone (Standard) is the analytical standard of 5,7-Dihydroxychromone (HY-N1970). This product is intended for research and analytical applications. 5,7-Dihydroxychromone is a flavonoid compound with antioxidant properties. 5,7-Dihydroxychromone induces Nrf2 nuclear translocation, increases Nrf2/ARE binding activity, and up-regulates Nrf2-dependent antioxidant genes HO-1, NQO1, GCLc. 5,7-Dihydroxychromone attenuates excessive ROS generation, inhibits activated caspase-3, caspase-9, cleaved PARP expression, and prevents neuronal apoptosis and cell death. 5,7-Dihydroxychromone increases LXRα and PPARγ mRNA expression, induces preadipocyte differentiation, and regulates blood glucose levels. 5,7-Dihydroxychromone inhibits radial growth of soil pathogenic fungi, radicle elongation of select seedlings, and transiently inhibits Bradyrhizobium sp. growth in high mannitol medium. 5,7-Dihydroxychromone can be used for the research of Parkinson’s disease, type 2 diabetes mellitus and pathogenic fungal infection .

HY-N3628

Coronarin A	Hedychium coronarium Koen. Structural Classification Terpenoids Diterpenoids Plants Zingiberaceae	mTOR Ribosomal S6 Kinase (RSK)
Coronarin A is an orally active natural compound that inhibits mTORC1 and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research .

HY-113015R

Stearoylethanolamide (Standard)	Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
Saxagliptin (hydrochloride) (Standard) is the analytical standard of Saxagliptin (hydrochloride). This product is intended for research and analytical applications. Saxagliptin hydrochloride (BMS-477118 hydrochloride) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin hydrochloride has the peotential for type 2 diabetes mellitus research .

HY-N1743

1-(4-Hydroxy-2-methoxyphenyl)-3-(4-hydroxy-3-prenylphenyl)	Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Moraceae Broussonetia kazinoki Sieb. et Zucc. Disease Research Fields Source Classification	Phosphatase
1-(4-Hydroxy-2-methoxyphenyl)-3-(4-hydroxy-3-prenylphenyl), isolated from Broussonetia kazinoki, shows in vitro inhibition of protein tyrosine phosphatase 1B (PTP1B) with an IC₅₀ of 13.00 μM. PTP1B is a negative regulator of insulin action and an important mediator in the pathogenesis of insulinresistance and non-insulin dependent diabetes mellitus. PTP1B is regarded as a significant target for type 2 diabetes .

HY-B1021R

Vincamine (Standard)	Apocynaceae Alkaloids Structural Classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	Reference Standards Free Fatty Acid Receptor
Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-N8250

cis-THSG	Structural Classification Simple Phenylpropanols Polygonaceae Phenylpropanoids Fallopia multiflora (Thunb.) Harald. Plants Source Classification	Topoisomerase PEPCK
cis-THSG is a selective and orally active DNA topoisomerase II inhibitor with no activity against DNA topoisomerase I. cis-THSG suppresses transcription of PEPCK. cis-THSG reduces blood glucose levels, ameliorates glucose intolerance, and alleviates insulin resistance in high fat diet-induced diabetic male CF-1 mice. cis-THSG can be used for the research of type 2 diabetes mellitus .

Cat. No.	Product Name	Chemical Structure

HY-15209S

Repaglinide-d5
Repaglinide-d₅ is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-B0254S

Glipizide-d11
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .

HY-P0014AS

Liraglutide-d8 tetraTFA
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-B0422S

Nateglinide-d5
Nateglinide-d₅ is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

HY-111372S

Finerenone-d3

Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-111372S1

Finerenone-d5

1 Publications Verification

Finerenone-d₅ (BAY 94-8862-d₅) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-14928S1

Lobeglitazone-d4
Lobeglitazone-d₄ is deuterium labeled Lobeglitazone. Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) .

HY-P0014S2

Liraglutide-13C6,15N TFA
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-15408S

Trelagliptin-13C,d3
Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin . Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-B1114S

Gliquidone-d6
Gliquidone-d₆ is deuterium labeled Gliquidone. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

HY-15461S

Ertugliflozin-d5
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin . Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-15461S1

Ertugliflozin-d9
Ertugliflozin-d₉ is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-10285S2

Saxagliptin-13C2
Saxagliptin- ¹³C₂ (BMS-477118- ¹³C₂) is ¹³C labeled Saxagliptin. Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research .

HY-10285S

Saxagliptin-15N,d2 hydrochloride
Saxagliptin-15N,d2 Hydrochloride (BMS-477118-15N,d2 Hydrochloride) is the ¹⁵N and deuterium labeled isotope of Saxagliptin (HY-10285). Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research .

HY-14806S2

Teneligliptin-d5

Teneligliptin-d₅ (MP-513-d₅) is deuterium labeled Teneligliptin. Teneligliptin (MP-513) hydrobromide hydrate is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC₅₀s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide hydrate improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus .

HY-W741755S1

5-Hydroxy saxagliptin-13C,d2-2 hydrochloride

5-Hydroxy saxagliptin- ¹³C,d₂-2 hydrochloride is the ¹³C- and deuterium labeled 5-Hydroxy saxagliptin hydrochloride. 5-Hydroxy saxagliptin hydrochloride is an active metabolite of Saxagliptin (HY-10285) and a potent and selective DPP-4 inhibitor. 5-Hydroxy saxagliptin hydrochloride has K_i values of 2.6 nM and 2.9 nM for humans and cynomolgus monkeys, respectively. 5-Hydroxy saxagliptin hydrochloride can be used in the research of type 2 diabetes mellitus .

Cat. No.	Product Name		Classification

HY-159694

IONIS PTP1BRx ISIS 404173		Antisense Oligonucleotides
IONIS PTP1BRx (ISIS 404173) is an antisense inhibitor of protein tyrosine phosphatase 1B (PTP-1B). IONIS PTP1BRx shows antidiabetic activity, and can be used for the study of insulin resistance and type 2 diabetes mellitus associated with obesity .

HY-159696

ISIS 449884		Antisense Oligonucleotides
ISIS 449884 is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-159696A

ISIS 449884 sodium		Antisense Oligonucleotides
ISIS 449884 sodium is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 sodium has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 sodium can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-159694A

IONIS PTP1BRx sodium ISIS 404173 sodium		Antisense Oligonucleotides
IONIS PTP1BRx (ISIS 404173) sodium is an antisense inhibitor of protein tyrosine phosphatase 1B (PTP-1B). IONIS PTP1BRx sodium shows antidiabetic activity, and can be used for the study of insulin resistance and type 2 diabetes mellitus associated with obesity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

type 2 diabetes mellitus

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products